Stoke Therapeutics and Biogen presented data at the 2025 American Epilepsy Society (AES) Annual Meeting supporting the potential of Zorevunersen for Dravet syndrome.
Long-term Phase 1/2a and open label extension (OLE) data showed durable seizure reductions and improvements in cognition, behavior, and quality of life.
Propensity score weighted analysis demonstrated reductions in seizures and improvements in cognition and behavior with dose levels similar to the ongoing Phase 3 EMPEROR study.
Durable Seizure Reductions
Long-term data showed increases in seizure-free days alongside improvements in cognition and behavior.
Comparative Analysis
Zorevunersen compared to natural history cohort showed significant improvements in seizure frequency and cognition.
Electroencephalogram (EEG) Analysis
EEG analysis supported a disease-modifying mechanism of action of Zorevunersen.
- The data presented suggest Zorevunersen may be a potential disease-modifying medicine for Dravet syndrome.
- Patients treated with Zorevunersen showed significant reductions in seizures and enhancements in cognitive functions.
- The analysis provides further understanding of the effects of Zorevunersen over time, boosting confidence in its potential benefits for patients.
The presented data at the AES meeting highlights the promising potential of Zorevunersen as a treatment for Dravet syndrome, providing hope for patients and their families. Further studies and safety data are anticipated to solidify its efficacy and safety profile.